Apropos to XP21279 the prodrug of L-dopa in Parkinson's, this is a recent PR related to GSK/IPXL competitive product - IPX066, regarding its second phase III trial, which I haven't seen mentioned here :
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.